Last reviewed · How we verify
Diacerhein — Competitive Intelligence Brief
marketed
Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Diacerhein (Diacerhein) — Laboratoires NEGMA.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diacerhein TARGET | Diacerhein | Laboratoires NEGMA | marketed | Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase | ||
| Artrodar | Artrodar | TRB Chemedica | phase 3 | Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase | ||
| Artrodar | DIACEREIN | phase 3 | diacerein | Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diacerhein CI watch — RSS
- Diacerhein CI watch — Atom
- Diacerhein CI watch — JSON
- Diacerhein alone — RSS
Cite this brief
Drug Landscape (2026). Diacerhein — Competitive Intelligence Brief. https://druglandscape.com/ci/diacerhein. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing